Future Challenges of Molecular Imaging in Oncology.

Q3 Medicine
Otmar Schober, Fabian Kiessling, Jürgen Debus
{"title":"Future Challenges of Molecular Imaging in Oncology.","authors":"Otmar Schober, Fabian Kiessling, Jürgen Debus","doi":"10.1007/978-3-032-21415-7_18","DOIUrl":null,"url":null,"abstract":"<p><p>Molecular imaging in oncology sits at the intersection of science, technology, and patient care, offering powerful tools for advancing diagnosis and personalized treatment. Future developments are driven by scientific ambition and clinical need, aiming to improve patient outcomes by translating complex biological insights into practical applications. Key opportunities include improved biomarkers, higher-resolution imaging, and multimodal integration. Chronobiology adds the time dimension, enabling dynamic monitoring of tumor processes, though challenges remain in quantifying kinetics due to technical and procedural constraints. Risks include tool-driven research, where technology dictates clinical questions, rather than vice versa. This calls for needs-based development guided by clear scientific objectives. AI, especially deep learning, promises integration of complex datasets, though ethical and professional responsibility in its use is critical. Barriers include high costs, limited reimbursement, regulatory hurdles, and logistical challenges. Clinical translation is often delayed by insufficient funding and a lack of standardized protocols. Despite these, real-world clinical benefit is increasingly influencing adoption. Interdisciplinary collaboration is essential, supported by translational centers and data-sharing networks. Ultimately, molecular imaging enhances the continuum between anatomical imaging, histology, and molecular profiling. It enables dynamic, noninvasive assessment of cancer biology, supporting adaptive and personalized treatment strategies and reinforcing its role in precision oncology.</p>","PeriodicalId":39880,"journal":{"name":"Recent Results in Cancer Research","volume":"225 ","pages":"1081-1088"},"PeriodicalIF":0.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent Results in Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-032-21415-7_18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Molecular imaging in oncology sits at the intersection of science, technology, and patient care, offering powerful tools for advancing diagnosis and personalized treatment. Future developments are driven by scientific ambition and clinical need, aiming to improve patient outcomes by translating complex biological insights into practical applications. Key opportunities include improved biomarkers, higher-resolution imaging, and multimodal integration. Chronobiology adds the time dimension, enabling dynamic monitoring of tumor processes, though challenges remain in quantifying kinetics due to technical and procedural constraints. Risks include tool-driven research, where technology dictates clinical questions, rather than vice versa. This calls for needs-based development guided by clear scientific objectives. AI, especially deep learning, promises integration of complex datasets, though ethical and professional responsibility in its use is critical. Barriers include high costs, limited reimbursement, regulatory hurdles, and logistical challenges. Clinical translation is often delayed by insufficient funding and a lack of standardized protocols. Despite these, real-world clinical benefit is increasingly influencing adoption. Interdisciplinary collaboration is essential, supported by translational centers and data-sharing networks. Ultimately, molecular imaging enhances the continuum between anatomical imaging, histology, and molecular profiling. It enables dynamic, noninvasive assessment of cancer biology, supporting adaptive and personalized treatment strategies and reinforcing its role in precision oncology.

肿瘤分子成像的未来挑战。
肿瘤分子成像处于科学、技术和患者护理的交叉点,为推进诊断和个性化治疗提供了强大的工具。未来的发展是由科学抱负和临床需求驱动的,旨在通过将复杂的生物学见解转化为实际应用来改善患者的治疗效果。关键的机会包括改进的生物标志物、更高分辨率的成像和多模式集成。时间生物学增加了时间维度,使肿瘤过程的动态监测成为可能,尽管由于技术和程序的限制,在量化动力学方面仍然存在挑战。风险包括工具驱动的研究,即技术决定临床问题,而不是相反。这就要求在明确的科学目标指导下以需求为基础的发展。人工智能,尤其是深度学习,有望整合复杂的数据集,尽管使用人工智能时的道德和职业责任至关重要。障碍包括高成本、有限的报销、监管障碍和后勤挑战。由于资金不足和缺乏标准化的协议,临床翻译常常被推迟。尽管如此,现实世界的临床效益正在日益影响其采用。在翻译中心和数据共享网络的支持下,跨学科合作至关重要。最终,分子成像增强了解剖成像、组织学和分子谱之间的连续性。它能够对癌症生物学进行动态、无创的评估,支持适应性和个性化的治疗策略,并加强其在精确肿瘤学中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书